Clinical Trials Browser

OTHER × Prostatic Neoplasms × relacorilant × Clear all

NCT03674814 2026-03-04

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms